JAMA Dermatology

<jats:sec id="ab-doi250022-4"><jats:title>Importance</jats:title><jats:p>Patients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event remains unclear.</jats:p></jats:sec><jats:sec id="ab-doi250022-5"><jats:title>Objective</jats:title><jats:p>To compare psoriasis risk in patients with AD who are prescribed dupilumab vs other systemic agents.</jats:p></jats:sec><jats:sec id="ab-doi250022-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This population-based retrospective cohort study with 3-year follow-up, with analyses completed on October 19, 2024, included 214 430 adult patients with AD  from the TriNetX Global Collaborative Network. Individuals newly prescribed dupilumab (dupilumab cohort) and those newly prescribed the other systemic agents without dupilumab exposure (control cohort) were included. Propensity score matching at a 1:1 ratio based on age, sex, race, comorbidities, laboratory measurements, and prior medications was conducted.</jats:p></jats:sec><jats:sec id="ab-doi250022-7"><jats:title>Exposures</jats:title><jats:p>Dupilumab vs the other systemic agents (corticosteroids, methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil).</jats:p></jats:sec><jats:sec id="ab-doi250022-8"><jats:title>Main Outcomes and Measures</jats:title><jats:p>The primary outcome was incident psoriasis. Cumulative incidence was assessed using Kaplan-Meier plots and risks via Cox regression.</jats:p></jats:sec><jats:sec id="ab-doi250022-9"><jats:title>Results</jats:title><jats:p>After matching, each cohort comprised 9860 patients, with 10 891 female individuals (55.2%), a mean (SD) age of 44.8 (20.3) years, 3582 African American or Black individuals (18.2%), 2004 Asian individuals (10.2%), and 9901 White individuals (50.2%). The 3-year cumulative psoriasis incidence was higher in the dupilumab cohort than the control cohort (2.86% vs 1.79%; <jats:italic>P</jats:italic> &amp;amp;lt; .001). The number needed to harm for psoriasis was 94 for dupilumab vs the other systemic agents. The dupilumab cohort showed an increased risk for psoriasis (hazard ratio [HR], 1.58; 95% CI, 1.25-1.99), although the risk for psoriatic arthritis was not significant (HR, 1.97; 95% CI, 0.75-5.18). This increased risk was also observed in various AD subgroups, including those without atopic comorbidities (HR, 1.42; 95% CI, 1.06-1.89) or with pretreatment immunoglobulin E levels less than 0.048 mg/dL (to convert to mg/L, multiply by 10; HR, 1.59; 95% CI, 1.26-2.01). The association between dupilumab and psoriasis was further supported by validation in patients with asthma without AD (HR, 2.13; 95% CI, 1.38-3.31).</jats:p></jats:sec><jats:sec id="ab-doi250022-10"><jats:title>Conclusions and Relevance</jats:title><jats:p>The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab’s established efficacy in treating AD.</jats:p></jats:sec>

Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.

N Engl J Med

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Lancet

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).

Br J Dermatol

Facial and neck erythema associated with dupilumab treatment: a systematic review.

J Am Acad Dermatol

Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: a retrospective cohort study.

Development of psoriasis during treatment with dupilumab: a systematic review.

Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review.

Dermatology

“De novo” psoriasis and relapse of psoriasis induced by dupilumab: three new cases and review of the literature.

J Clin Med

An asthmatic case of psoriasiform eruption caused by administration of dupilumab.

Allergol Int

Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns.

Dermatol Ther

Dupilumab-induced skin-associated side effects in patients with chronic rhinosinusitis with nasal polyposis.

J Dermatol

Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.

Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an interleukin–4/13 inhibitor.

Arthritis Rheumatol

Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management.

JAAD Case Rep

Contrasting pathogenesis of atopic dermatitis and psoriasis–part I: clinical and pathologic concepts.

J Allergy Clin Immunol

Contrasting pathogenesis of atopic dermatitis and psoriasis–part II: immune cell subsets and therapeutic concepts.

Can atopic eczema and psoriasis coexist? a systematic review and meta-analysis.

Skin Health Dis

Concomitant atopic dermatitis and psoriasis - a retrospective review.

J Dermatolog Treat

Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?

Curr Opin Immunol

IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells.

Proc Natl Acad Sci U S A

Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy.

Rheumatology (Oxford)

Unexpected connections of the IL-23/IL-17 and IL-4/IL-13 cytokine axes in inflammatory arthritis and enthesitis.

Semin Immunol

Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris.

Ann Rheum Dis

Genetically proxied interleukin-13 inhibition is associated with risk of psoriatic disease: a mendelian randomization study.

Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: a population-based cohort study.

Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.

Lancet Rheumatol

European guideline (EuroGuiDerm) on atopic eczema: part I—systemic therapy.

J Eur Acad Dermatol Venereol

New biological treatments for asthma and skin allergies.

Allergy

Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009.

Pharmacoepidemiol Drug Saf

Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden—a population-based register study.

PLoS One

Validity of diagnostic codes for identification of psoriasis patients in Korea.

Ann Dermatol

Atopic dermatitis endotypes and implications for targeted therapeutics.

Diversity of atopic dermatitis and selection of immune targets.

Ann Allergy Asthma Immunol

Psoriasis.

T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17–type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases.

J Invest Dermatol

De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort.

Efficacy and safety of dupilumab in clinical practice: one year of experience on 165 adult patients from a tertiary referral centre.

Dermatol Ther (Heidelb)

Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis.

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.

Nat Med

Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.

Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report.

Comment on: development of psoriasis during treatment with dupilumab: a systematic review.

Cost-effectiveness analysis of abrocitinib compared with other systemic treatments for severe atopic dermatitis in Spain.

Pharmacoecon Open

Dupilumab-associated arthritis: a dermatology-rheumatology perspective.

Am J Clin Dermatol

Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis.

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization.

Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features.

Extrinsic and intrinsic types of atopic dermatitis.

J Dermatol Sci

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis.

The role of Janus kinase signaling in the pathology of atopic dermatitis.

Patients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event remains unclear.
To compare psoriasis risk in patients with AD who are prescribed dupilumab vs other systemic agents.
This population-based retrospective cohort study with 3-year follow-up, with analyses completed on October 19, 2024, included 214 430 adult patients with AD from the TriNetX Global Collaborative Network. Individuals newly prescribed dupilumab (dupilumab cohort) and those newly prescribed the other systemic agents without dupilumab exposure (control cohort) were included. Propensity score matching at a 1:1 ratio based on age, sex, race, comorbidities, laboratory measurements, and prior medications was conducted.
Dupilumab vs the other systemic agents (corticosteroids, methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil).
The primary outcome was incident psoriasis. Cumulative incidence was assessed using Kaplan-Meier plots and risks via Cox regression.
After matching, each cohort comprised 9860 patients, with 10 891 female individuals (55.2%), a mean (SD) age of 44.8 (20.3) years, 3582 African American or Black individuals (18.2%), 2004 Asian individuals (10.2%), and 9901 White individuals (50.2%). The 3-year cumulative psoriasis incidence was higher in the dupilumab cohort than the control cohort (2.86% vs 1.79%; P < .001). The number needed to harm for psoriasis was 94 for dupilumab vs the other systemic agents. The dupilumab cohort showed an increased risk for psoriasis (hazard ratio [HR], 1.58; 95% CI, 1.25-1.99), although the risk for psoriatic arthritis was not significant (HR, 1.97; 95% CI, 0.75-5.18). This increased risk was also observed in various AD subgroups, including those without atopic comorbidities (HR, 1.42; 95% CI, 1.06-1.89) or with pretreatment immunoglobulin E levels less than 0.048 mg/dL (to convert to mg/L, multiply by 10; HR, 1.59; 95% CI, 1.26-2.01). The association between dupilumab and psoriasis was further supported by validation in patients with asthma without AD (HR, 2.13; 95% CI, 1.38-3.31).
The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab's established efficacy in treating AD.

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab.

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab

Clinical Summary

What was studied

Key findings

Clinical implications

Related Questions